CML vaccines as a paradigm of the specific immunotherapy of cancer

Blood Reviews

Volumn 14, Issue 2, 2000, Pages 111-120

  Pinilla Ibarz, J ^a   Cathcart, K ^a   Scheinberg, D A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; HLA ANTIGEN; LEUKEMIA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN;

CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DENDRITIC CELL; HUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0033866145     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.2000.0127     Document Type: Review

References (70)

1. Rowley J. D. A new consistent chromosomal abnormality in chronic myelogenous leukemia, identified by quinacrine fluorescence and Giemsa staining. Nature. 243:1973;290.
2. de Klein A., Geurts van Kesel A., Grosvels G. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature. 300:1982;765.
3. Heisterkamp N., Stephenson J. R., Groffen J. Localization of the c-abl oncogene adjacent to a translocation breakpoint in chronic myelocytic leukemia. Nature. 306:1983;239.
4. Shtivelman E., Lifshitz B., Gale R. P., Canani E. Fused transcript of abl and bcr genes in chronic myelogenus leukemia. Nature. 315:1985;550.
5. Grosveld G., van Agthoven T., de Klein A. The chronic myelocytic cell line K562 contains a breakpoint in ber and produces a chimeric bcr-abl transcript. Mol Cell Biol. 6:1986;607.
6. Ben-Neriah Y., Daley G. Q., Mes-Massan A. M., Wirte O. N., Baltimore D. The chronic myelogenus leukemia-specific P210 protein the product of the bcr/abl hybrid gene. Science. 233:1986;212.
7. Kloetzer W., Kurzrock R., Smith L., Talpaz M., Spiller M., Gutterman J., Arlinghaus R. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has associated tyrosinase protein kinase activity. Virology. 140:1985;230.
8. Shtivelman E., Lifshitz B., Gale R. P., Roe B. A., Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell. 47:1986;277.
9. Yotnda P., Firat H., Garcia-Pons F., Garcia Z., Gourru G., Vernant J. P., Lemmonier F. A., Leblond V., Langlade-Demoyen P. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest. 101:1998;2290.
10. Nieda M., Nicol A., Kikuchi A., Kashiwase K., Taylor K., Suzuki K., Tadokoro K., Juji T. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemia cells from patients with chronic myeloid leukemia. Blood. 91:1998;977.
11. ten Bosch G. J. A., Joosten A. M., Kessler J. H., Melief C. J. M., Leekesma O. C. Recognition of BCR-ABL positive leukemic blast by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood. 9:1996;3522.
12. Smit W. M., Rijnbeek M., van Bergen C. A. M., Fibbe W., Willemze R., Falkemburg J. H. F. T cells recognizing leukemic CD34+ progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogenic stem cell transplantation. Proc Natl Acad Sci USA. 95:1998;10152.
13. Choudhury A., Gajewski J. L., Liang J. C., Popat U., Claxton D. F., Kliche K. O., Andreeff M., Champlin R. E. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 89:1997;1133.
14. Kolb H. J., Mittermuller J., Clemm C. H., Holler E., Ledderose G., Brehm G., Heim M., Wilmans W. Donor leucocyte transfusions for treatment of recurrent myelogenous leukemia in bone marrow transplant patients. Blood. 76:1990;2462.
15. Mackinnon S., Papadopoulus E. B., Carabasi M. H., Reich L., Collins N. H., Boulad F., Castro-Malaspina H., Childs B. H., Gillio A. P., Kernan N. A., Small T. N., Young J. W., O'Reilly R. J. Adoptive immunotherapy evaluating scalating doses of donors leucocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft versus leukemia from graft versus host disease. Blood. 86:1995;1261.
16. Giralt S., Hester J., Huh Y., Hirsch-Ginsberg C., Rondon G., Seong D., Lee M., Gajewski J., Van Besien K., Khouri I. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 86:1995;4337.
17. Coleman S., Perera P., Fisher J., Hoy T., Burnet A. K., Lim S. H. Abnormal TCR V repertoire in patients with chronic myeloid leukemia. Br J Hematol. 90:1995;358.
18. Coleman S., Fisher J., Hoy T., Burnet A. K., Lim S. H. Autologous MHC-dependent leukemia-reactive T lymphocytes in a patient with chronic myeloid leukemia. Leukemia. 10:1996;483.
19. Lim S. H., Coleman S., Bull A., O'Callaghan U., Evely R., Booth M. Cyclosporin A/alpha interferon -induced autologous graft-verus host disease following peripheral blood stem cell transplant for chronic myeloid leukemia: a clinico-pathological study. Bone Marrow Transplant. 20:1997;83.
20. Musashi M., Abe S., Yamada T., Tanaka J., Gotohda Y., Maeda S., Sato Y., Morioka M., Sakurada K., Minagawa T., Asaka M., Miyakazi T. Spontaneous remission in a patient with chronic myelogenus leukemia. New Engl J Med. 336:1997;337.
21. Bose S., Deininger M., Gora-Tybor J., Goldman J. M., Melo J. V. The presence of typical and atypical bcr-abl fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 92:1998;3362.
22. Biernaux C., Loos M., Sels A., Huez G., Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood. 86:1995;3118.
23. Sokal J. E., Aungst C. W., Snyderman M., Gomez G. Immunotherapy of chronic myelocityc leukemia: effects of different vaccination schedules. Ann N Y Acad Sci. 277:1976;267.
24. Melief C. J. M. Tumor erradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res. 58:1992;143.
25. Toes R. E. M., Ossendorp F., Offringa R., Melief C. J. M. CD4 T cells and their role in antitumor immune responses. J Exp Med. 189:1999;753.
26. Jacobson S. J., Richert R., Bidisson W. E., Satinsky A., Hartzman R. J., McFarland H. F. Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens. J Immunol. 133:1984;754.
27. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., Levitsky H. The central role of CD4+ T cells in the antitumor response. J Exp Med. 188:1998;2357.
28. Bocchia M., Wentworth P. A., Southwood S., Sidney J., McGraw K., Scheinberg D. A., Sette A. Specific binding of leukemia oncogene fusion protein peptide to HLA class I molecules. Blood. 85:1995;2680.
29. Bocchia M., Korontsvit T., Xu Q., Mackinnon S., Yang S. Y., Sette A., Scheiberg D. A. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 87:1996;3587.
30. Greco G., Fruci D., Accapezzato D., Barnaba V., Nisini R., Alimena G., Montefusco E., Vigneti E., Butler R., Tanigaki N., Tosi R. Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia. 10:1996;693.
31. Buzyn A., Ostankovitch M., Zerbib A., Kemula M., Connan F., Varet B., Guillet J. G., Choppin J. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol. 27:1997;2066.
32. Osman Y., Takahashi M., Zheng Z., Koike T., Liu A., Furukawa T., Aoki S., Aizawa Y. Generation of bcr-abl specific cytotoxicity T lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia. 13:1999;166.
33. Chen W., Quin H., Reese V., Cheever M. A. CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein. J Immunother. 21:1998;257.
34. Alexander-Miller M. A., Leggat G. R., Sarin A., Berzofsky J. A. Role of the antigen, CD8 and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med. 184:1996;485.
35. Kersh G. J., Kersh E. N., Fremont D. H., Allen P. M. High and low-potency ligands with similar affinities for the TCR: The importance of kinetics in TCR signaling. Immunity. 9:1998;817.
36. Yee C., Savage P. A., Lee P. P., Davis M. M., Greenberg P. D. Isolation of high avidity melanoma-reactive CTL from heterogeneous population using peptide-MHC tetramers. J Immunol. 162:1999;2227.
37. ten Bosch G. J. A., Toornvliet A. C., Fride T., Melief C. J. M., Leekesma O. C. Recognition of peptides corresponding to the joining region of p210 bcr-abl protein by human T cells. Leukemia. 9:1995;1344.
38. Pawelec G., Max H., Halder T., Bruserud O., Merl A., da Silva P., Kalbacher H. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood. 88:1996;2118.
39. Mannering S. I., McKenzie J. L., Fearnley D. B., Hart D. N. HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respon to dendritic cells pulsed with b3a2 peptide and antigen presenting cells exposed to b3a2 containing cell lysates. Blood. 90:1997;290.
40. Yasukawa M., Ohminami H., Kaneko S., Yakushijin Y., Nishimura Y., Inokuchi K., Miyakuni T., Nakao S., Kishi K., Kubonishi I., Dan K., Fujita S. CD4+ cytotoxic T cell clones specific for bcr-abl b3a2 fusion protein augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood. 92:1998;3355.
41. Chen W., Peace D. J., Rovira D. K., You S., Cheever M. A. T cell immunity to the joining region of p210 BCR-ABL protein. Proc Natl Acad Sci USA. 89:1992;1468.
42. ten Bosch G. J. A., Kessler J. H., Joosten A. M., Bres-Vloemans A. A., Geluk A., Godthelp B. C., van Bergen J., Melief C. J.M., Leeksma O. C. A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Iib2a2 construct. Blood. 94:1999;1038-1045.
43. Cathcart K. N., Pinilla-Ibarz J., Korontsvit T., Lai L. T., Tempst P., Scheinberg D. A. T cell immunity to Philadelphia chromosome (Ph1) positive acute lymphocytic leukemia (ALL). p190 bcr-abl breakpoint derived peptides can generate in vitro T cell responses. Blood. 94:1999;78a.
44. Pinilla-Ibarz J., Cathcart K., Korontsvit T., Soignet S., Bocchia M., Caggiano J., Lai L., Jimenez J., Kolitz J., Scheinberg D. A. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 95:2000.
45. Yotnda P., Garcia F., Peuchmaur M., Grandchamp B., Duval M., Lemonier F., Vilmer E., Langlade-Demoyen P. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Invest. 102:1998;455.
46. Yun C., Senju S., Fujita H., Tsuji Y., Irie M., Matsushita S., Nishimura Y. Augmentation of immune response by altered peptide ligands of the antugenic peptide in a human CD4+ T cell clone reacting t o TEL/AML1 fusion protein. Tissue Antigens. 54:1999;153.
47. Cardoso A. A., Alves P., Veiga J. P., Haining W. N., Afonso H., Sallan S. E., Golub T., Nadler L. M. Immunity to the fusion gene TEL-AML1 represents only a part of the overall anti leukemia T cell mediated immunity generated in TEL-AML1+ patients. Blood. 94:1999;76a.
48. Gambacorti-Passerini C., Grignani F., Arienti F., Pandolfi P. P., Pelicci P. G., Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein PML/RAR alfa present in acute promyelocytic leukemia cells. 1993;Blood. p. 1369.
49. Dermime S., Bertazzoli C., Marchesi E., Ravagnani F., Blaser K., Corneo G. M., Pogliani E., Parmiani G., Gambacorti-Passerini C. Lack of T cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Clin Cancer Res. 2:1996;593-600.
50. Pollock J. L., Westervelt P., Schrimpf K., Ley T. J. Immunologic responses directed against APML cells. Blood. 94:1999;81a.
51. Ohminami H., Yasukawa M., Kaneko S., Yakushijin Y., Abe Y., Kasahara Y., Ishida Y., Fujita S. Fas-independent and nonapoptotic cytotoxicity mediated by a human CD4(+) T cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide. Blood. 93:1999;925-935.
52. Molldrem J., Dermime S., Parker K., Jiang Y. Z., Mavroudis D., Hensel N., Fukushima P., Barrett A. J. Targeted T cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 88:1996;2450-2457.
53. Molldrem J. J., Clave E., Jiang Y. Z., Mavroudis D., Raptis A., Hensel N., Agarwala V., Barrett A. J. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 90:1997;2529-2534.
54. Molldrem J. J., Lee P. P., Wang C., Champlin R. E., Davis M. M. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59:1999;2675-2681.
55. Ohminami H., Yasukawa M., Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T lymphocyte clone specific for WT1 peptide. Blood. 95:2000;286-293.
56. Bellantuono I., Gao L., Elsaesser A., Marley S., Gordon M., Goldman J., Stauss H. Selective elimination of leukemic progenitors by allorestricted CTL specific for Wilms tumor antigen-1 (WT-1). Blood. 94:1999;532a.
57. den Haan J. M., Sherman N. E., Blokland E., Huczko E., Koning F., Drijfhout J. W., Skipper J., Shabanowitz J., Hunt D. F., Engelhard V. H., Goulmy E. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science. 268:1995;1476-1480.
58. den Haan J. M., Meadows L. M., Wang W., Pool J., Blokland E., Bishop T. L., Reinhardus C., Shabanowitz J., Offringa R., Hunt D. F., Engelhard V. H., Goulmy E. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 279:1998;1054-1057.
59. Falkenburg J. H., Goselink H. M., van der Harst D., van Luxemburg-Heijs S. A., Kooy-Winkelaar Y. M., Faber L. M., de Kroon J., Brand A., Fibbe W. E., Willemze R. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med. 174:1991;27-33.
60. Faber L. M., van Luxemburg-Heijs S. A., Willemze R., Falkenburg J. H. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med. 176:1992;1283-1289.
61. Smit W. M., Rijnbeek M., van Bergen C. A., Fibbe W. E., Willemze R., Falkenburg J. H. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci USA. 95:1998;10152-10157.
62. Falkenburg J. H., Wafelman A. R., Joosten P., Smit W. M., van Bergen C. A., Bongaerts R., Lurvink E., van der Hoorn M., Kluck P., Landegent J. E., Kluin-Nelemans H. C., Fibbe W. E., Willemze R. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood. 94:1999;1201-1208.
63. Mutis T., Verdijk R., Schrama E., Esendam B., Brand A., Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 93:1999;2336-2341.
64. Banchereau J., Steinman R. M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
65. Smit W. M., Rijnbeek M., van Bergen C. A., de Paus R. A., Vervenne H. A., van de Keur M., Willemze R., Falkenburg J. H. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Hum Immunol. 53:1997;216-223.
66. Heinzinger M., Waller C. F., von den Berg A., Rosenstiel A., Lange W. Generation of dendritic cells from patients with chronic myelogenous leukemia. Ann Hematol. 78:1999;181-186.
67. Engels F. H., Koski G. K., Bedrosian I., Xu S., Luger S., Nowell P. C., Cohen P. A., Cohen P. A., Czerniecki B. J. Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells. Proc Natl Acad Sci USA. 96:1999;10332-10337.
68. Eibl B., Ebner S., Duba C., Bock G., Romani N., Erdel M., Gachter A., Niederwieser D., Schuler G. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T cell response. Genes Chromosomes Cancer. 20:1997;215-223.
69. Lim S. H., Coleman S., Bailey-Wood R. In vitro cytokine-primed leukaemia cells induce in vivo T cell responsiveness in chronic myeloid leukaemia. Bone Marrow Transplant. 22:1998;1185-1190.
70. Westermann J., Richter G., Kopp J., Korner I., Dohner H., Dohner K., Dorken B., Pezzutto A. Dendritic cells for vaccination in bcr/abl positive chronic myeloid leukemia. Blood. 94:1999;281b.